---
layout: post
title: "高盛公司将基石药业评级下调至中性 目标价8.60港元"
date: 2022-03-16 02:16:52 +0800
categories: cailianshe
tags: 财联社新闻
---
<p style="display:none;height:1px;overflow:hidden;"> </p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.02616" data-code="02616|116|5" data-code2="02616|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02616&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 02616_0" data-code="K 02616|116|5" data-code2="K 02616|116|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>高盛公司分析师Ziyi Chen将基石药业评级由之前的买进下调至中性，目标价8.60港元，即上涨97%。基石药业的平均目标价为15港元。<br /></p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202203162310554523>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)